Technical Analysis for NERV - Minerva Neurosciences, Inc

Grade Last Price % Change Price Change
F 3.35 1.52% 0.05
NERV closed down 4.35 percent on Wednesday, January 20, 2021, on 1.5 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up
Historical NERV trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 1.52%
Wide Bands Range Expansion 1.52%
Above Upper BB Strength 1.52%
Overbought Stochastic Strength 1.52%
Upper Bollinger Band Touch Strength 1.52%
Crossed Above 50 DMA Bullish -2.90%
MACD Bullish Centerline Cross Bullish -2.90%
Pocket Pivot Bullish Swing Setup -2.90%
Volume Surge Other -2.90%
Wide Range Bar Range Expansion -2.90%
Older End-of-Day Signals for NERV ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 4 hours ago
Down 2 % about 4 hours ago
Down 1% about 4 hours ago
Up 2% about 4 hours ago
Up 1% about 4 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Minerva Neurosciences, Inc Description

Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Neuroscience Schizophrenia Parkinson's Disease Psychoactive Drugs Depressive Disorder Major Depressive Disorder Neurochemistry Treatment Of Parkinson's Disease Ketones Central Nervous System Disease Central Nervous System Diseases Treatment Of Major Depressive Disorder Antidepressants Insomnia Janssen Pharmaceutica Treatment Of Central Nervous System Diseases Cyren Dopamine Investigational New Drug

Is NERV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.215
52 Week Low 1.81
Average Volume 935,928
200-Day Moving Average 4.48
50-Day Moving Average 2.96
20-Day Moving Average 2.60
10-Day Moving Average 2.76
Average True Range 0.20
ADX 33.49
+DI 43.23
-DI 14.70
Chandelier Exit (Long, 3 ATRs ) 3.14
Chandelier Exit (Short, 3 ATRs ) 2.85
Upper Bollinger Band 3.17
Lower Bollinger Band 2.03
Percent B (%b) 1.11
BandWidth 44.05
MACD Line 0.06
MACD Signal Line -0.06
MACD Histogram 0.1226
Fundamentals Value
Market Cap 140.83 Million
Num Shares 42.7 Million
EPS -1.38
Price-to-Earnings (P/E) Ratio -2.40
Price-to-Sales 2.82
Price-to-Book 2.13
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.77
Resistance 3 (R3) 3.76 3.59 3.69
Resistance 2 (R2) 3.59 3.47 3.60 3.66
Resistance 1 (R1) 3.45 3.40 3.37 3.46 3.64
Pivot Point 3.28 3.28 3.24 3.29 3.28
Support 1 (S1) 3.14 3.16 3.06 3.15 2.96
Support 2 (S2) 2.97 3.09 2.98 2.94
Support 3 (S3) 2.83 2.97 2.91
Support 4 (S4) 2.84